Targeting the hepatocyte growth factor-cMET axis in cancer therapy

George R. Blumenschein, Gordon B. Mills, Ana M. Gonzalez-Angulo

    Research output: Contribution to journalReview article

    187 Scopus citations

    Abstract

    The hepatocyte growth factor (HGF) and its receptor, the transmembrane tyrosine kinase cMET, promote cell proliferation, survival, motility, and invasion as well as morphogenic changes that stimulate tissue repair and regeneration in normal cells but can be co-opted during tumor growth. MET overexpression, with or without gene amplification, has been reported in a variety of human cancers, including breast, lung, and GI malignancies. Furthermore, high levels of HGF and/or cMET correlate with poor prognosis in several tumor types, including breast, ovarian, cervical, gastric, head and neck, and non-small-cell lung cancers. Gene amplification and protein overexpression of cMET drive resistance to epidermal growth factor receptor family inhibitors, both in preclinical models and in patients. It is increasingly apparent that the HGF-cMET axis signaling network is complex, and rational combinatorial therapy is needed for optimal clinical efficacy. Better understanding of HGF-cMET axis signaling and the mechanism of action of HGF-cMET inhibitors, along with the identification of biomarkers of response and resistance, will lead to more effective targeting of this pathway for cancer therapy.

    Original languageEnglish (US)
    Pages (from-to)3287-3296
    Number of pages10
    JournalJournal of Clinical Oncology
    Volume30
    Issue number26
    DOIs
    StatePublished - Sep 10 2012

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Targeting the hepatocyte growth factor-cMET axis in cancer therapy'. Together they form a unique fingerprint.

  • Cite this